QLGN insider filings

Qualigen Therapeutics, Inc. — 25 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2022-08-04. Screen QLGN transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for QLGN between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Qualigen Therapeutics, Inc.

FiledFormInsiderReported transactionsSource
2022-08-044Ritter Ira E. — DirectorGrant/award (A): 40,000 (derivative) @ $0EDGAR
2022-08-044ARSHAD TARIQ — SVP/Chief Medical OfficerGrant/award (A): 102,000 (derivative) @ $0EDGAR
2022-08-044Abdul-Ahad Wajdi — Vice President, R & D, CSOGrant/award (A): 80,000 (derivative) @ $0EDGAR
2022-08-044Lotz Christopher L. — Vice President of Finance, CFOGrant/award (A): 100,000 (derivative) @ $0EDGAR
2022-08-044David Richard A. — DirectorGrant/award (A): 40,000 (derivative) @ $0EDGAR
2022-08-044Poirier Michael S. — Chairman and CEO, DirectorGrant/award (A): 375,000 (derivative) @ $0EDGAR
2022-08-044BROIDRICK AMY S. — President/CSO, DirectorGrant/award (A): 130,000 (derivative) @ $0EDGAR
2022-08-044Korenberg Matthew E — DirectorGrant/award (A): 40,000 (derivative) @ $0EDGAR
2022-08-044Sinha Shishir K. — VP, COO & SecretaryGrant/award (A): 100,000 (derivative) @ $0EDGAR
2022-08-044Kruger Kurt H — DirectorGrant/award (A): 40,000 (derivative) @ $0EDGAR
2022-08-044EMERY SIDNEY W JR — DirectorGrant/award (A): 40,000 (derivative) @ $0EDGAR
2022-06-224Poirier Michael S. — Chairman and CEO, DirectorPurchase (P): 30,000 @ $0.57EDGAR
2022-06-154BROIDRICK AMY S. — President/CSO, DirectorPurchase (P): 30,000 @ $0.62EDGAR
2021-12-104BROIDRICK AMY S. — President/ChiefStrategyOfficer, DirectorGrant/award (A): 300,000 (derivative) @ $0EDGAR
2021-12-104ARSHAD TARIQ — SVP/Chief Medical OfficerGrant/award (A): 300,000 (derivative) @ $0EDGAR
2021-08-204Kruger Kurt H — DirectorPurchase (P): 4,000 @ $1.23 · Purchase (P): 4,000 @ $1.22EDGAR
2021-05-184ARSHAD TARIQ — SVP/Chief Medical OfficerGrant/award (A): 100,000 (derivative) @ $0EDGAR
2021-04-264BROIDRICK AMY S. — EVP, Chief Strategy Officer, DirectorPurchase (P): 4,500 @ $2.03EDGAR
2021-04-214Poirier Michael S. — Chairman, CEO & President, DirectorPurchase (P): 11,005 @ $1.80EDGAR
2021-04-194Lotz Christopher L. — Vice President of Finance, CFOPurchase (P): 2,700 @ $1.86EDGAR
2020-12-304Kruger Kurt H — DirectorPurchase (P): 4,000 @ $2.94EDGAR
2020-12-294BROIDRICK AMY S. — Executive VP, CSO, DirectorGrant/award (A): 150,000 (derivative) @ $0EDGAR
2020-12-084EMERY SIDNEY W JR — DirectorGrant/award (A): 50,000 (derivative) @ $0EDGAR
2020-11-234Kruger Kurt H — DirectorPurchase (P): 1,400 @ $3.55 · Purchase (P): 4,600 @ $3.46EDGAR
2020-08-284BROIDRICK AMY S. — DirectorGrant/award (A): 50,000 (derivative) @ $0EDGAR

Recent 8-K events — Qualigen Therapeutics, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-138-K2.02 — Results of Operations and Financial Condition
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-268-K1.01 — Entry into a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
3.02 — Unregistered Sales of Equity Securities
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-268-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-148-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-298-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-298-K5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-268-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2026-08-188-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-078-K2.02 — Results of Operations and Financial Condition
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-318-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR

Registration filings — Qualigen Therapeutics, Inc.

Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=QLGN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs